Immune Response News and Research

RSS

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

Novavax, Inc. a clinical-stage vaccine company, released the final results from a Phase II clinical trial evaluating Novavax's trivalent seasonal influenza Virus-like particle (VLP) vaccine candidate in healthy adults. The study enrolled healthy volunteers 18 to 49 years in age who were immunized with a single injection of Novavax's trivalent seasonal influenza VLP vaccine matched to the influenza strains recommended for the 2008-2009 influenza vaccine.

29 Mar 2010

High fructose corn syrup linked to skyrocketing rates of obesity

According to the Centers for Disease Control and Prevention, the rates of obesity in the United States have skyrocketed since the introduction of high fructose corn syrup in 1970. In that time, obesity rates have gone from 15 percent of the U.S. population to roughly one-third.

29 Mar 2010

Role Tregs play in therapeutic HIV vaccines

Like a skittish driver slamming the brakes, a special class of T cells may be limiting the effectiveness of therapeutic vaccines for HIV by slowing the immune system response too soon, report University of Pittsburgh health science researchers in the current issue of PLoS ONE. Their study, the first to look at the role of regulatory T cells in therapeutic HIV vaccines, may help researchers improve the efficacy of such vaccines by devising methods to circumvent the braking mechanism of these cells.

27 Mar 2010

NIH awards $15M grant to UMDNJ-New Jersey Medical School

For the second time in less than one month, the University of Medicine and Dentistry of New Jersey-New Jersey Medical School has been awarded a coveted $15 million grant by the National Institutes of Health.

27 Mar 2010

Complex relation between breastfeeding, prolactin and breast cancer

Women who are diagnosed with breast cancer in the 12 months after they have completed a pregnancy are 48% more likely to die than other young women with breast cancer according to new research to be presented at the seventh European Breast Cancer Conference (EBCC7) in Barcelona today (Friday).

26 Mar 2010

Tumors mimic lymphoid tissue and alter host's immune response

A new mechanism explaining how tumors escape the body's natural immune surveillance has recently been discovered at EPFL (Ecole Polytechnique Fédérale de Lausanne) in Switzerland. The study shows how tumors can create a tolerant microenviroment and avoid attack by the immune system by mimicking key features of lymph nodes.

26 Mar 2010

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, providing information on rebound viral genetic diversity in HIV patients treated with the personalized immunotherapy following antiretroviral therapy (ART) interruption. The data were discussed in a poster session at the Keystone Symposia Global Health Series HIV Vaccines meeting, held March 21-26, 2010 in Banff, Canada.

26 Mar 2010

Natural chemicals from blackcurrants may reduce lung inflammation in allergy-induced asthma

A preliminary study by New Zealand company Plant & Food Research shows that natural chemicals from blackcurrants may help breathing in some types of asthma.

26 Mar 2010

Experimental vaccine can help delay IBD and colon cancer

An experimental vaccine against an abnormal protein found in some tumors has the potential to delay the onset of inflammatory bowel disease (IBD) and in turn prevent progression to colon cancer, according to researchers at the University of Pittsburgh School of Medicine.

25 Mar 2010

Optimism may be good for your health

Feeling better about the future might help you feel better for real. In a new study, psychological scientists Suzanne Segerstrom of the University of Kentucky and Sandra Sephton of the University of Louisville studied how law students' expectations about the future affected their immune response.

24 Mar 2010

Researchers develop new compound to inhibit HIV transmission

A compound that can inhibit the transfer of HIV from one cell to another has been developed by researchers at the Institut de Biologie Structurale Jean-Pierre Ebel.

22 Mar 2010

Trauma patients with undiagnosed Helicobacter infections: Some drugs may not be effective

A Kansas State University study aimed at alleviating intestinal damage in trauma patients digressed to an important finding that could affect medication given to the individuals.

19 Mar 2010

Genes role in protecting intestinal tract from colitis may lead to potential targets for treatment

Scientists report a protein made by a gene already associated with a handful of human inflammatory immune diseases plays a pivotal role in protecting the intestinal tract from colitis.

19 Mar 2010

JDRF hosts Diabetes Research Symposium to focus on type 1 diabetes

For the second consecutive year in Montreal, Juvenile Diabetes Research Foundation's Diabetes Research Symposium will be opening its doors at Fairmont Queen Elizabeth this Sunday, March 21st, from 1:00 p.m. to 4:00 p.m. Free and open to all, this event will focus on type 1 (juvenile) diabetes, and aims to inform the general public about JDRF's groundbreaking research progress.

19 Mar 2010

Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has published new research findings on ActA as a potential, anti-cancer component and a new complement to the Company’s evolving proprietary Listeria technology platform.

19 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

Immune Response News and Research

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

High fructose corn syrup linked to skyrocketing rates of obesity

Role Tregs play in therapeutic HIV vaccines

NIH awards $15M grant to UMDNJ-New Jersey Medical School

Complex relation between breastfeeding, prolactin and breast cancer

Tumors mimic lymphoid tissue and alter host's immune response

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Natural chemicals from blackcurrants may reduce lung inflammation in allergy-induced asthma

Experimental vaccine can help delay IBD and colon cancer

Optimism may be good for your health

Researchers develop new compound to inhibit HIV transmission

Trauma patients with undiagnosed Helicobacter infections: Some drugs may not be effective

Genes role in protecting intestinal tract from colitis may lead to potential targets for treatment

JDRF hosts Diabetes Research Symposium to focus on type 1 diabetes

Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Therapeutic may not be effective on trauma patients with undiagnosed Helicobacter infections

Stress during pregnancy may raise infant’s risk to asthma and allergy

Scientists discover switch mechanism that controls cells' trafficking system

Research shows Caspase-1 protein plays a key role in the process of inflammation and colon cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News